Pfizer Inc.

11/19/2021 | Press release | Archived content

Arvinas And Pfizer Announce Updated Phase 1 Dose Escalation Data For ARV-471 To Be Presented In Spotlight Poster Session At 2021 San Antonio Breast Cancer Symposium